Wall Street expects a year-over-year decline in earnings on higher revenues when Perrigo (PRGO) reports results for the quarter ended September 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on November 5. On ...

Wall Street expects flat earnings compared to the year-ago quarter on higher revenues when Performance Food Group (PFGC) reports results for the quarter ended September 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be r ...

Wall Street expects a year-over-year increase in earnings on flat revenues when Quantum Computing Inc. (QUBT) reports results for the quarter ended September 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss ...

核心观点 - 公司预计在2025年第三季度财报中呈现营收增长但盈利同比下降的局面 [1] - 实际业绩与市场预期的对比是影响其短期股价的关键因素 [1] - 基于盈利ESP为负值和Zacks Rank评级较低，公司不太可能超出盈利预期 [12] 财务预期 - 预计季度每股收益为0.72美元，同比下降20.9% [3] - 预计季度营收为8.5331亿美元，同比增长4.6% [3] - 过去30天内，季度共识每股收益预期被上调了1.73% [4] 盈利预测模型分析 - 最准确估计低于共识估计，导致盈利ESP为-9.79% [12] - 股票当前的Zacks Rank为4级（卖出） [12] - 盈利ESP模型仅对正值的预测能力显著 [9] 历史业绩表现 - 上一报告季度，公司实际每股收益为0.83美元，超出预期0.71美元，超出幅度达16.90% [13] - 在过去四个季度中，公司有三次超过了共识每股收益预期 [14] 市场影响因素 - 盈利超出或未达预期并非股价变动的唯一基础，其他因素如未预见的催化剂同样重要 [15] - 尽管历史表现良好，但当前的预测指标组合使得难以断定本次财报将超预期 [12][17]

Wall Street expects a year-over-year decline in earnings on higher revenues when Acadia Pharmaceuticals (ACAD) reports results for the quarter ended September 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on November 5, might help the stock move higher if these key numbers are better ...

The market expects Alector (ALEC) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they mi ...

业绩预期 - 公司预计在截至2025年9月的季度实现营收6.3669亿美元，同比增长5.9% [3] - 季度每股收益预期为1.64美元，同比增长0.6% [3] - 财报预计将于11月4日发布 [2] 预期修正趋势 - 过去30天内，季度共识每股收益预期被下调0.87%至当前水平 [4] - 最准确估计值低于共识预期，导致收益ESP为-6.42%，表明分析师近期对公司盈利前景转趋悲观 [12] 历史业绩表现 - 上一报告季度，公司实际每股收益为1.75美元，远超1.46美元的预期，意外增长达19.86% [13] - 在过去四个季度中，公司每次均超出共识每股收益预期 [14] 市场影响与预测模型 - 实际业绩与预期的对比是影响股价短期走势的关键因素 [1] - 公司的Zacks评级为第3级（持有） [12] - 结合当前负值的收益ESP和第3级Zacks评级，难以明确预测公司将超出共识每股收益预期 [12]

核心观点 - Ultragenyx (RARE) 预计在截至2025年9月的季度实现营收增长和亏损收窄，但其盈利可能不及预期，股价短期走势将受实际业绩与预期对比的影响 [1][2] - 同行业的Vertex Pharmaceuticals (VRTX) 则更有可能实现盈利超预期 [18][19][20] Ultragenyx (RARE) 财务预期 - 公司预计季度每股亏损为1.23美元，较去年同期改善12.1% [3] - 预计季度营收为1.6755亿美元，同比增长20.1% [3] - 在过去30天内，共识每股收益预期被下调0.43% [4] Ultragenyx (RARE) 盈利惊喜预测 - 盈利ESP（预期惊喜预测）为-12.47%，表明分析师近期对其盈利前景转趋悲观 [12] - 公司目前的Zacks评级为第3级（持有） [12] - 上一季度公司每股亏损1.17美元，较预期亏损1.27美元高出7.87% [13] - 在过去四个季度中，公司有两次盈利超出预期 [14] Vertex Pharmaceuticals (VRTX) 财务预期 - 公司预计季度每股收益为4.55美元，同比增长3.9% [18] - 预计季度营收为30.4亿美元，同比增长9.7% [19] - 在过去30天内，共识每股收益预期被下调0.6% [19] Vertex Pharmaceuticals (VRTX) 盈利惊喜预测 - 盈利ESP为+0.57%，反映最准确估计高于共识预期 [19] - 结合其Zacks第3级（持有）评级，公司很可能超出共识每股收益预期 [20] - 在过去四个季度中，公司有两次盈利超出预期 [20]

uniQure (QURE) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may ...

核心观点 - 市场预期Leidos在2025年第三季度营收增长但盈利同比下降，实际业绩与预期的对比将影响股价[1] - 结合盈利ESP和Zacks Rank模型分析，Leidos当前不太可能超出盈利预期[12] - 尽管历史上有超预期记录，但其他因素也可能影响股价，公司目前并非有吸引力的盈利超预期标的[15][17] 财务预期 - 预计季度每股收益为2.61美元，同比下降10.9%[3] - 预计季度营收为42.7亿美元，同比增长1.8%[3] - 过去30天内共识每股收益预期上调了0.26%[4] 盈利预测模型分析 - Zacks盈利ESP通过对比最准确预期和共识预期来预测偏差[7][8] - 正值的盈利ESP结合Zacks Rank 1-3级时，预测盈利超预期的准确率近70%[10] - Leidos的最准确预期低于共识预期，盈利ESP为-2.30%，且Zacks Rank为3级，难以预测其将超越盈利预期[12] 历史业绩表现 - 上一季度报告每股收益3.21美元，超出2.63美元的预期，超出幅度达22.05%[13] - 在过去四个季度中，公司每次均超越了共识每股收益预期[14]